Format

Send to

Choose Destination
Int J Clin Pharmacol Ther. 2018 Nov;56(11):551-554. doi: 10.5414/CP203323.

NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients
.

Abstract

OBJECTIVES:

Skin rash is a common adverse event induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here, we aimed to predict factors that reduce EGFR-TKI-related skin rash.

MATERIALS AND METHODS:

We conducted a single-center, retrospective study to predict factors that reduce skin rash in patients undergoing treatment for non-small cell lung cancer (NSCLC) with EGFR-TKIs using Cox proportional hazards model.

RESULTS:

Cox proportional hazard analysis revealed that coadministration of non-steroidal anti-inflammatory drug (NSAID) had protective effects against rash. Steroid coadministration showed a trend to being effective in reducing rash.

CONCLUSION:

NSAIDs may be useful in preventing EGFR-TKI-related skin rash.
.

PMID:
30232957
DOI:
10.5414/CP203323

Supplemental Content

Full text links

Icon for Dustri-Verlag Dr. Karl Feistle GmbH & Co. KG
Loading ...
Support Center